Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

651 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC, Lee SH, Chiu LC, Lee CS, Wu CE, Kuo SC, Ju JS, Huang AC, Li SH, Ko HW, Yang CT, Wang CC. Hsu PC, et al. Among authors: yang ct. Target Oncol. 2023 Mar;18(2):195-207. doi: 10.1007/s11523-023-00946-w. Epub 2023 Feb 20. Target Oncol. 2023. PMID: 36805452 Free PMC article.
Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer.
Wang CC, Tseng CC, Hsiao CC, Chang HC, Chang LT, Fang WF, Leu S, Wang YH, Tsai TH, Yang CT, Chen CH, Yip HK, Ho CK, Lin MC. Wang CC, et al. Among authors: yang ct. Biomed Res Int. 2014;2014:173401. doi: 10.1155/2014/173401. Epub 2014 Jun 29. Biomed Res Int. 2014. PMID: 25061601 Free PMC article. Clinical Trial.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D, Chuang CY, Chang FK, Tsai CM, Perng RP, Chih-Hsin Yang J. Chiu CH, et al. Among authors: yang ct. J Thorac Oncol. 2015 May;10(5):793-799. doi: 10.1097/JTO.0000000000000504. J Thorac Oncol. 2015. PMID: 25668120 Free article.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
651 results